Immune Cell Processing Service
Clinical-grade CAR-T, CAR-NK, TIL, and DC vaccine manufacturing, with automated workflows, high success rates, and full traceability.
Key advantages:
-
High quality: High CAR-positive rates with minimal impurities, fully compliant with clinical standards.
-
High success rate: Manufacturing success rate exceeding 95%.
-
Traceability: Closed-loop management covering sample collection, transportation, preparation, delivery, and infusion.
-
Modularity: Process design can be flexibly combined based on project characteristics.
-
Automation: Critical and complex steps are automated to ensure consistency and efficiency.
Our immune cell processing platform is built upon CAR-T cell manufacturing and a robust quality control system, enabling the production of multiple clinical-grade cell preparations that meet IND submission and clinical research requirements.
The platform is designed with a flexible and modular structure, supporting a wide range of cell therapy products including CAR-T, DC, NK, CAR-NK, and TIL therapies. Both viral vector-based and non-viral transduction processes are supported, and the platform operates at an internationally advanced level.
Get in Touch
We’re here to answer your questions and explore potential collaborations.